✦ LIBER ✦

5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

✍ Scribed by Makhija, S.; Glenn, D.; Ueland, F.; Dizon, D.; Paton, V.; Lin, C.Y.; Amler, L.; Sliwkowski, M.; Strauss, A.; Matulonis, U.

Book ID: 123566363
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 77 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(07)71174-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OCEANS: A Randomized, Double-Blind, Plac

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

✍ Aghajanian, C.; Blank, S. V.; Goff, B. A.; Judson, P. L.; Teneriello, M. G.; Hus 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 348 KB

Efficacy in Patient Subgroups in OCEANS,

Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)

✍ C. Aghajanian; S.V. Blank; B. Goff; P.L. Judson; S. Makhija; S.K. Sharma; L.R. N 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Late-Breaking Abstract 5: Results from a

Late-Breaking Abstract 5: Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

✍ C. Aghajanian; S. Blank; B. Goff; P. Judson; L. Nycum; M. Sovak; J. Yi; A. Husai 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB